ClinicalTrials.gg
Not yet recruitingNCT07134855Updated Aug 21, 2025

Mitigating Chronic Respiratory Disease Through the Lens of Multimorbidity (MARES3)

An observational study in Chronic Obstructive Pulmonary Disease (COPD), Asthma and Preserved Ratio Impaired Spirometry (PRISM), sponsored by University College, London. Not yet recruiting at 2 sites in Brazil. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by University College, London · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
473
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University College, London.

Started
2025
with 3 others
Observational
9 of 14
4 open now
Registered
14th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, this one is one of 4 that started in 2025, is one of 9 observational ones, and was the 14th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

4 of the 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by University College, London, or all of them as a file.
02

Study summary

The investigators aim to investigate how individuals attending primary healthcare (PHC) services in Brazil for treatment of non-communicable diseases (NCDs), identified there as having abnormal spirometry or as being at high risk for lung health problems (such as asthma and chronic obstructive pulmonary disease-COPD, collectively referred to as chronic respiratory disease (CRDs)) using the COLA-6 questionnaire, are able to access diagnostic testing and treatment.

The investigators will re-assess people diagnosed with abnormal spirometry in the MARES1 study (NCT07050823) or identified as being at high-risk for CRDs in the MARES2 study (NCT07093021). The estimated sample size is 309 from MARES1 and 164 from MARES2 for a total sample size of 473.

Qualitative interviews will be conducted with a diverse subsample of 30 participants to explore their experience accessing CRD diagnosis and treatment, including barriers and facilitators, while all participants will undergo basic data collection and spirometry.

Read the detailed description

The investigators aim to investigate how individuals attending primary healthcare (PHC) services in Brazil for treatment of non-communicable diseases (NCDs), identified there as having abnormal spirometry or as being at high risk for lung health problems (such as asthma and chronic obstructive pulmonary disease-COPD, collectively referred to as chronic respiratory disease (CRDs)) using the COLA-6 questionnaire, are able to access diagnostic testing and treatment.

The study will be carried out in PHC services, including Basic Health Units (BHUs) and Family Health Units (FHUs), located in the municipalities of São Carlos and São Paulo, both in the state of São Paulo, Brazil.

Individuals are being followed up after participation in MARES1 study (NCT07050823) and MARES2 study (NCT07093021), and had been originally recruited from PHC services, including BHUs and FHUs, located in the municipalities of São Carlos and São Paulo, Brazil. People were recruited if they were attending a PHC service for care of a NCD.

At the research visit, all participants will be asked about access to care. In addition, all participants will have application of the CAAT questionnaire, and the ACQ-7 questionnaire for those with asthma, and all participants will have measurement of pre- and post-bronchodilator spirometry and Fraction of Exhaled Nitric Oxide (FeNO).

A semi-structured interviews will be conducted with a sample of 30 patients diagnosed with abnormal spirometry results: 10 with COPD, 10 with asthma, and 10 with PRISm or restriction. These face-to-face interviews will use open-ended questions, be audio-recorded, transcribed, and anonymized before analysis. Participants will be randomly selected to ensure diversity in gender, age, socioeconomic status, and employment background. The interview will explore how participants accessed healthcare services for diagnostic confirmation and treatment, and how this process affected their health status. Topics will include barriers and facilitators, how doubts were clarified, the type of education they received regarding the disease, diagnosis, and treatment, and whether any changes occurred in their lifestyle or routine following diagnosis or treatment.

The qualitative analysis of the interviews will follow Braun and Clarke, which consists of six phases: 1) Familiarization with the data set; 2) Coding; 3) Generation of initial themes; 4) Development and review of themes; 5) Refinement, definition and naming of themes; and 6) Writing. Descriptive statistics will be used to describe responses to questionnaires and lung function testing, including changes from the values recorded at recruitment to MARES1 and MARES2.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Preserved Ratio Impaired Spirometry (PRISM)

Keywords

  • chronic obstructive pulmonary disease
  • asthma
  • multi-morbidity
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with a non-communicable disease and found to be at high risk for, or newly diagnosed with a chronic respiratory disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participated in MARES1 and MARES2, which recruited people with non-communicable diseases attending primary healthcare services in Brazil, identified as being at high-risk for, or confirmed as having chronic respiratory diseases.

Exclusion criteria

Exclusion Criteria:

  • No consent to take part in MARES3.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
473 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Barriers and facilitators to accessing care for those with newly diagnosed / suspected chronic respiratory disease in primary healthcare services in Brazil.

    Barriers and facilitators to accessing care for those with newly diagnosed / suspected chronic respiratory disease in primary healthcare services in Brazil, assessed at qualitative interviews.

    Time frame: A single assessment visit conducted six months following diagnosis (participants from MARES1) / identification of being at high risk for chronic respiratory disease (participants from MARES2).

Secondary outcomes

  1. Spirometry

    Pre-and post bronchodilator spirometry

    Time frame: A single assessment visit conducted six months following diagnosis (participants from MARES1) / identification of being at high risk for chronic respiratory disease (participants from MARES2).

  2. Disease Control Questionnaire

    Chronic Airways Assessment Test (CAAT) questionnaire

    Time frame: A single assessment visit conducted six months following diagnosis (participants from MARES1) / identification of being at high risk for chronic respiratory disease (participants from MARES2).

  3. FeNO

    Fractional Exhaled Nitric Oxide

    Time frame: A single assessment visit conducted six months following diagnosis (participants from MARES1) / identification of being at high risk for chronic respiratory disease (participants from MARES2).

  4. Disease Control Questionnaire

    ACQ-7 (Asthma Control Questionnaire)

    Time frame: A single assessment visit conducted six months following diagnosis (participants from MARES1) / identification of being at high risk for chronic respiratory disease (participants from MARES2).

07

Study locations

2 sites
08

References and documents

Publications

  • Mendes RG, Leonardi NT, Castello-Simoes V, Kawakami DMO, Souza JVR, Schafauser-Segundo NS, Simoes RP, Pinto FG, Araujo GHG, da Silva MMC, Moriguchi CS, Franco FJBZ, Pires Di Lorenzo VA, Jordan R, Martins S, Siddharthan T, Al Sharmah S, Barber J, Hurst JR. Mitigating chronic respiratory disease through the lens of multimorbidity: the MARES mixed-methods study protocol. BMJ Open. 2026 Jan 16;16(1):e109950. doi: 10.1136/bmjopen-2025-109950. PubMed 41545050 ↗

Individual participant data

Plan to share: No — We have no plans to share individual responses from qualitative interviews.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Jul 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 21, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134855
Collaborators
Universidade Federal de Sao Carlos
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 21, 2025

Study contacts

Viviane Castello
Contact
vivianecastello@ufscar.br
(+5516) 99992 4777
John R Hurst, PhD FRCP
principal investigator · University College London Hospitals
Renata G Mendes, DFisio
principal investigator · Federal University of Sao Carlos (UFScar), Brasil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion